Novo Nordisk Files Lawsuit Challenging Medicare Drug Price Talks

Novo Nordisk became the latest pharmaceutical company to file a lawsuit against the Biden administration’s drug price negotiation program.

The manufacturer filed the lawsuit Friday in US District Court for the District of New Jersey, saying the implementation of the the drug pricing provisions of the Inflation Reduction Act violate both the Fifth and First Amendments. Novo Nordisk’s drugs—selected as among the first 10 up for price talks with Medicare—include the insulin products Fiasp and NovoLog.

The challenge comes as deadlines for the company and other drugmakers to agree to participate in the talks with the Medicare agency are imminent. ...